Sunshine Heart, Inc. — Form 10-Q Summary
Reporting period: Quarter ended June 30, 2014; financial comparisons are with the three and six months ended June 30, 2013, as applicable. The filing identifies the registrant as Sunshine Heart, Inc. (the metadata names Nuwellis, Inc.). Amounts below are in U.S. dollars; financial statement amounts are in thousands unless noted.
Business context
Sunshine Heart was an early-stage medical-device company developing the C-Pulse Heart Assist System for moderate-to-severe heart failure. The device had FDA authorization for a U.S. pivotal clinical study and CE Mark approval in Europe, but was not approved for commercial sale in the United States. Revenue came from clinical-study device implants, not commercial sales.
Financial performance and liquidity
| Metric | Q2 2014 | Q2 2013 | Six months 2014 | Six months 2013 |
|---|---|---|---|---|
| Net sales | $0 | $0 | $59 | $0 |
| SG&A expense | $2,243 | $2,150 | $4,604 | $4,126 |
| Research and development expense | $4,413 | $3,150 | $8,476 | $5,576 |
| Operating loss | $(6,656) | $(5,300) | $(13,021) | $(9,702) |
| Net loss | $(6,380) | $(4,220) | $(12,712) | $(8,619) |
| Loss per share | $(0.38) | $(0.35) | $(0.75) | $(0.81) |
No commercial-scale gross margin was reported; with minimal clinical-study sales and product costs expensed in R&D, a meaningful margin comparison is not available. In the first half, one device implant generated $59,000 of revenue; none generated revenue in Q2.
For the six months ended June 30, 2014, operating cash use was $11.922 million, investing cash use was $113,000, and financing provided $16,000. Cash declined by $12.011 million to $42.125 million from $54.136 million at December 31, 2013. The comparable 2013 period used $7.571 million in operating cash and received $14.910 million in financing proceeds.
At June 30, 2014, total assets were $43.372 million, including $42.125 million cash; current liabilities were $2.849 million, with no long-term liabilities reported. The company reported no material capital-expenditure commitments and no off-balance-sheet arrangements. It had an accumulated deficit of $113.724 million.
Material changes and management outlook
- First-half R&D expense rose 52% year over year, primarily due to added personnel and clinical-research infrastructure for North American and European studies. Management expected R&D expense to remain above prior-year levels through 2014.
- First-half SG&A expense rose 11.6%, attributed to infrastructure investment. Management expected continued infrastructure spending and quarter-to-quarter variability in share-based compensation.
- Management expected revenue to remain minimal until enrollment in the North American pivotal study increased and reimbursement was established in selected European post-market study countries.
- The first-half 2014 Australian R&D tax-credit benefit was $265,000, versus $1.077 million in 2013. Management expected future Australian refunds, if any, to decrease, and had not determined whether a refund would be available for the period ended June 30, 2014.
Risks, contingencies, and unusual items
- Funding and going concern: The company expected continued losses and operating cash outflows. Management said continued operations depended on raising additional capital and developing and commercializing its product; unsuccessful or insufficient funding could prevent it from continuing as a going concern. No related balance-sheet adjustments were recorded.
- Development and regulatory risk: Results depend on clinical-study outcomes, regulatory acceptance and approvals, and successful commercialization. The C-Pulse System was not approved for U.S. commercial sale.
- Potential dilution: Additional equity or debt financing might be needed and might be unavailable on acceptable terms. The Aspire Capital agreement provided for potential future stock purchases subject to its terms and limits.
- Tax-credit benefit: The 2014 benefit reflected a refund for an earlier Australian tax period, rather than a recurring operating revenue stream.
- No material legal proceedings were reported. Management concluded disclosure controls and procedures were effective at a reasonable-assurance level as of June 30, 2014.
Important facts for investors to verify
- Clinical-study enrollment, progress, and outcomes for the U.S. pivotal and European post-market studies, along with relevant regulatory developments.
- Cash burn and financing needs in subsequent filings; management did not provide a quantified runway or formal financial guidance in this filing.
- Whether the company obtained additional Australian R&D tax-credit refunds and how those compare with the prior-year refund.
- The relationship between the filing’s registrant, Sunshine Heart, Inc., and the metadata’s company name, Nuwellis, Inc.